Action ALPMY ASTELLAS PHARMA INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Astellas Pharma Inc. OTC Markets

Actions

ALPMY

US04623U1025

Marché Fermé - OTC Markets
Autres places de cotation
 21:51:56 20/06/2024 		Varia. 5j. Varia. 1 janv.
9,39 USD -1,05% Graphique intraday de Astellas Pharma Inc. -2,09% -21,09%
21/05 Astellas annonce une collaboration avec YASKAWA pour créer un écosystème de thérapie cellulaire innovant grâce à l'intégration des technologies pharmaceutiques et robotiques CI
08/05 Astellas inaugure un nouveau centre d'innovation ultramoderne de 90 millions de dollars sur la côte ouest, dans le corridor biotechnologique de South San Francisco CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
Malin Corp investee signs agreement with Astellas Pharma
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
MÄRKTE ASIEN/Freundlich - Yen lotet neue Tiefs aus
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
Astellas Pharma Inc. Announces Board and Committee Retirements
European Commission Approves Astellas Pharma Label Extension for Xtandi
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Lupin Launches Mirabegron Extended-Release Tablets in US
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4503
  4. Action ALPMY
  5. Actualités Astellas Pharma Inc.
  6. Autres langues